Anaphylaxis

Urticaria and angioedema with oral mucocutaneous involvement were commonly labeled as anaphylaxis upon presentation.

The proportion of anaphylaxis episodes was higher in the cohort of patients with peanut allergies, compared to a control group of patients with non-peanut food allergies.

Data pooled from 5 trials show a consistent and manageable safety profile for continued treatment with PALFORZIA.

Prior to the investigation, peanut allergy was often linked to high rates of anaphylaxis, with its prevalence in children and adolescents surpassing that found in adult patients.

Investigators believe the ALDORADO trial could properly diagnose the accuracy of open food challenges in comparison to the traditionally used double-blind placebo-controlled food challenge in pediatric patients with food allergies.

Investigators report that the small number of adverse events from the vaccine were successfully treated, with the remaining participants experiencing no allergic responses.

The investigative team in Canada found that pre-pregnancy weight may possibly influence a child’s risk of developing pediatric allergic diseases.

Investigators link early atopic manifestations and other complications to tree nut allergy, which account for most of all food related deaths by anaphylaxis.

Staff from schools across the United Kingdom express desire for enhanced staff preparedness and internal allergy policy review after being surveyed by investigators.

Post-survey responses show educators were eager to learn more about how to prevent students from experiencing food-anaphylactic reactions.

In data presented during AAAAI 21, researchers compared the 2006 and 2016 versions of the diagnostic criteria proposed by the NIAD/FAAN.

In the initial report, investigators find just 2.5 cases of anaphylaxis per million doses of the Moderna COVID-19 vaccine.

In nearly 1.9 million doses of the COVID-19 vaccine there has been only 21 total cases of anaphylaxis.

The rate of ED cases have decreased over years, yet proper patient follow-up is still lacking.

The Allergenic Products Advisory Committee voted in favor Friday to support the BLA data for what could become the first drug indicated for food allergy desensitization.

Investigators found that peanut allergy immunotherapy was associated with a greater risk of anaphylaxis, epinephrine use, and serious adverse events compared to avoidance or placebo.

The first generation of food allergy treatments is nearing the market. What could be next is more individualized therapies.

What other specialties should become more involved in the network of care for allergic patients?

Is the US population having allergies diagnosed correctly, and are allergies on the rise?

Pediatric peanut allergy trials have proven successful. Now where do researchers look next?

What does the typical patient have to treat aside from their allergy, and what are their treatment goals?

Have current guidelines been fitted to consider the future of immunotherapy research?

UNC investigators consider the role current food allergy trials may play in addressing gaps of knowledge on patient individualization.

Why it may be critical to reassess dosing practices being practiced in investigative food allergy therapies.

About 9 of 10 patients were able to safely consume foods containing peanuts in an eight-year, longitudinal observational study.

The therapy was further assessed in asthmatic patients with comorbid chronic rhinosinusitis and with or without nasal polyposis.

UNC School of Medicine colleagues Edwin Kim, MD, MS, and Scott Commins, MD, PhD, explain how the discussion around food allergy care has progressed this year.

Investigative therapy PVX108 showed a favorable tolerability and safety profile in patients with peanut allergies.

Why both physicians and patients need to be on the same page when considering food allergy oral immunotherapy.

Why peanut allergy therapies are prioritized in early trials, and how far out are complimentary therapies to the ones currently being investigated.